Archives: Speakers

秦祯（Claire Chin）女士是生命科技投资与人工智能交叉领域的战略领袖，拥有逾15年横跨临床医疗、战略咨询、风险投资及AI产业的跨领域经验。现任INTELLIGEN AI首席产业顾问兼首席战略官，主导生物大语言模型生态建设。她拥有西北大学凯洛格商学院MBA及上海交通大学临床医学本硕学位，兼具顶尖医疗专业与商业战略双重背景。曾任阿里健康董事总经理兼创新药投资负责人，主导了超7000万美元的投资，并推动被投企业达成亚洲最大AI药物授权交易（单项目13亿美元）。目前致力于构建30余家机构的AI协同创新网络，加速药物研发与精准医疗突破。

Ms. Claire Chin is a strategic leader at the intersection of life sciences investment and AI with over 15 years of cross-sector expertise spanning clinical medicine, strategic consulting, venture capital, and artificial intelligence. As Chief Industrial Advisor and Chief Strategy Officer at INTELLIGEN AI, she spearheads biomedical LLM ecosystem development. Holding an MBA from Kellogg School of Management and a clinical medicine dual degree from Shanghai Jiao Tong University, she uniquely bridges deep healthcare and business domains. As former Managing Director at Alibaba Health, head of investment in biopharma, her track record includes leading a $70M+ life science portfolio and securing Asia’s largest AI drug licensing deal ($1.3B per asset). She now pioneers collaborative AI innovation across 30+ institutions to transform drug discovery and precision medicine.

James Liu , Licensed Attorney，holding LL.M.s both from the University of Manchester and one of the top China’s university, as well as a Ph.D. in Management, with twenty years of dedicated experience in the biopharmaceutical and high-tech investment sectors. As a founding practitioner (Founder), I lead the formulation of corporate-wide strategy and development roadmaps, concentrating on core drivers for business growth: effectively integrating critical resources (particularly governmental relations and public policy resources), establishing deep public-private collaborative ecosystems, accurately discerning industry policy trends and driving their translation into execution to ensure corporate compliance and sustained competitive advancement. Leveraging comprehensive expertise spanning R&D, manufacturing, operations management, to investment and financing, I am committed to accelerating the industrialization of innovative achievements and steering organizations toward high-quality, sustainable growth.

刘 James，执业律师，拥有国内外著名高校生物化学本科、双法学硕士及管理学博士学位，于生物医药与高科技投资领域持续深耕二十年。 作为创业实践者（Founder），主导制定企业整体战略与发展路径，聚焦驱动业务增长的核心要素：高效整合关键资源（尤其是政府关系与公共政策资源）、构建深度政企协同生态、精准研判产业政策趋势并推动落地转化，确保企业合规经营与竞争力持续提升。 凭借覆盖研发、生产、管理至投融资的综合经验，致力于促进创新成果产业化，引领企业实现高质量的可持续增长。

With over 30 years of clinical research experience, Gonzalo brings medical, scientific, and business insights to oncology drug development. His understanding of the clinical development – ranging from feasibility assessments, medical monitoring oversight, regulatory strategy, and patient safety enables him to provide valuable guidance to our biopharma partners.

Gonzalo is a board-certified Medical Oncologist with 15+ years of practice in the clinic and as an investigator before leading Global Oncology Medical Teams at the most renowned CROs.

Dominic Jackson is a forward-thinking clinical data professional with deep experience across Central Lab, CRO, and Sponsor environments. He brings a unique, end-to-end perspective on how data can be used more intelligently and creatively in clinical research.

Dominic is particularly interested in how emerging technologies, cross-functional collaboration, and smarter data strategies can unlock new efficiencies and insights. He’s a strong advocate for rethinking traditional approaches and embracing innovation to improve outcomes for both sponsors and patients.

Experienced R&D Director with deep passion for the flavour industry and broad experiences across several multinational companies including Sensient, Kerry and now McCormick Flavour Division. Driven by a dynamic, inspired, entrepreneurial, disruptive, trusting, collaborative, purposeful, excellence-obsessed approach to spark the R&D engine for Business value creation and Company’s growth.

Richard Graham, founder of Mirador Therapeutics and TruTechnologies, is a seasoned leader with extensive experience in business operations, corporate strategy, fundraising, scientific research, and therapeutics development. He excels at aligning corporate strategy with scientific expertise and building partnerships with executives, board members, and investors.

A proven leader in global team management, Rick has successfully driven large-scale R&D programs from concept to completion, consistently achieving ambitious milestones. His work has advanced therapeutics through late-stage development, contributing to the approvals of Erivedge™, Kadcyla™, Kyprolis™, Perjeta™, and Yupelri™.

Alyson Nicks serves as one of two Investigations Branch Supervisory Consumer Safety Officers at the Otay Mesa Port of Entry in the Division of Southwest Imports. She currently serves in the Public Health Service Commissioned Corps in the Pharmacy Category.

Alyson joined the FDA in 2020 as a Consumer Safety Officer at the Otay Mesa Port of Entry. Prior to her FDA career, she worked as a Clinical Pharmacist at the Gallup Indian Health Service and Albuquerque Indian Health Center, where she also served as Pharmacy Residency Director and Acting Facilities Director.

She earned both her Doctor of Pharmacy degree and Bachelor of Science degree from Wilkes University. In her current role, Alyson oversees FDA import operations for Team 7 at the Otay Mesa Port of Entry.